Affiliation:
1. Sechenov First Moscow State University (Sechenov University)
2. Sechenov First Moscow State University (Sechenov University);
Pirogov Russian National Research Medical University
3. Sechenov First Moscow State University (Sechenov University);
Consultative and diagnostic center № 2 of the Moscow Healthcare Department
Abstract
Aim. The aim is to study the correlation between the vaccination rate (VR) and mortality rate of patients with COVID-19 (MpCOV).Methods. The countries with gross domestic product per capita corrected for purchasing power parity (GDP PPP) over $-10,000 were selected for an ecologic study. The city-states and countries with a population of 1,000,000 were excluded. The number of patients who died from COVID-19 within a week was divided by the number of patients diagnosed with COVID-19 within a week 20 days earlier to calculate MpCOV.Results. We included 85 countries. VR (r = –0.604; p < 0.001) and GDPpcPPP level (p = 0.202), is an independent determinant of MpCOV. There was no significant difference in MpCOV between groups of countries with VR < 20 % and 20–39 % (1.96 [1.21; 4.67] vs. 1.96 [1.01; 3.36] %; p = 0.464). MpCOV was higher in countries where VR were lower when groups of countries with VR of 20–39 %, 40–59 %, 60–79 %, and ≥80 % were compared (1.96 [1.01; 3.36] vs. 1.11 [0.76; 1.64] vs. 0.50 [0.39; 1.00] vs. 0.16 [0.10; 0.21]; p = 0.003; p = 0.020, and p = 0.008).Conclusions. An increase in VR correlates with a decrease in MpCOV.
Publisher
Russian Gastroenterolgocial Society
Subject
Gastroenterology,Hepatology,Surgery,Internal Medicine
Reference15 articles.
1. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. DOI: 10,1016/S0140-6736(21)00234-8
2. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15. DOI: 10,1056/NEJMoa2034577
3. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. DOI: 10,1056/NEJMoa2035389
4. Cohn B.A., Cirillo P.M., Murphy C.C., Krigbaum N.Y., Wallace A.W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2021:eabm0620. DOI: 10,1126/science.abm0620
5. Maslennikov R., Ivashkin V., Vasilieva E., Chipurik M., Semikova P., Semenets V., et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther. 2021;69:102039. DOI: 10,1016/j.pupt.2021.102039
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献